In multiple myeloma, JQ1 treatment led to specific MYC inhibition [15] (figure 2), while in CLL, BET inhibition led to the downregulation of multiple survival pathways involved in CLL biology [90]. This evidence concerns the gene DNER and B-cell chronic lymphocytic leukemia.